CN102939108A - 缀合的凝血因子viii - Google Patents

缀合的凝血因子viii Download PDF

Info

Publication number
CN102939108A
CN102939108A CN2011800218881A CN201180021888A CN102939108A CN 102939108 A CN102939108 A CN 102939108A CN 2011800218881 A CN2011800218881 A CN 2011800218881A CN 201180021888 A CN201180021888 A CN 201180021888A CN 102939108 A CN102939108 A CN 102939108A
Authority
CN
China
Prior art keywords
fviii
biocompatible polymer
pharmaceutical composition
cysteine residues
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800218881A
Other languages
English (en)
Chinese (zh)
Inventor
W·亨利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEVERTON LICENCE HOLDINGS Ltd
Original Assignee
LEVERTON LICENCE HOLDINGS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102939108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LEVERTON LICENCE HOLDINGS Ltd filed Critical LEVERTON LICENCE HOLDINGS Ltd
Publication of CN102939108A publication Critical patent/CN102939108A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN2011800218881A 2010-04-30 2011-04-28 缀合的凝血因子viii Pending CN102939108A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII
GB1007357.5 2010-04-30
PCT/GB2011/000662 WO2011135307A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii

Publications (1)

Publication Number Publication Date
CN102939108A true CN102939108A (zh) 2013-02-20

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800218881A Pending CN102939108A (zh) 2010-04-30 2011-04-28 缀合的凝血因子viii

Country Status (26)

Country Link
US (1) US20130150302A1 (enExample)
EP (1) EP2563402A1 (enExample)
JP (1) JP5870088B2 (enExample)
KR (1) KR20130055619A (enExample)
CN (1) CN102939108A (enExample)
AP (1) AP2012006575A0 (enExample)
AU (1) AU2011247147B2 (enExample)
BR (1) BR112012027590A2 (enExample)
CA (1) CA2797058A1 (enExample)
CL (1) CL2012003039A1 (enExample)
CO (1) CO6660443A2 (enExample)
CR (1) CR20120579A (enExample)
EA (1) EA201290938A1 (enExample)
EC (1) ECSP12012314A (enExample)
GB (2) GB201007357D0 (enExample)
IL (1) IL222566A (enExample)
MX (1) MX2012012683A (enExample)
MY (1) MY160922A (enExample)
NI (1) NI201200160A (enExample)
NZ (1) NZ603939A (enExample)
PE (1) PE20130254A1 (enExample)
PH (1) PH12012502150A1 (enExample)
RU (1) RU2012144555A (enExample)
SG (1) SG184906A1 (enExample)
WO (1) WO2011135307A1 (enExample)
ZA (1) ZA201208989B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111788220A (zh) * 2018-01-12 2020-10-16 财团法人牧岩生命科学研究所 体内持续释放重组凝血因子ⅷ及其制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101557830B (zh) 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
RU2595442C2 (ru) 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
AP2014008049A0 (en) * 2012-04-16 2014-11-30 Cantab Biopharmaceuticals Patents Ltd Optimised subcuraneous therapeutic agents
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
EP3816181A4 (en) 2018-05-18 2022-04-20 Zhengzhou Gensciences Inc. Improved fviii fusion protein and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009130602A2 (en) * 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
WO2010010324A1 (en) * 2008-07-21 2010-01-28 Polytherics Limited Novel reagents and method for conjugating biological molecules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2633916T3 (es) * 2004-11-12 2017-09-26 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
DK1835938T3 (da) * 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
JP2009532351A (ja) * 2006-03-31 2009-09-10 バクスター・インターナショナル・インコーポレイテッド ペグ化第ｖｉｉｉ因子
EP2209494B1 (en) 2007-10-09 2016-07-20 Polytherics Limited Novel conjugated proteins and peptides
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009130602A2 (en) * 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
WO2010010324A1 (en) * 2008-07-21 2010-01-28 Polytherics Limited Novel reagents and method for conjugating biological molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAISONG MEI ET AL.: "Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment", 《BLOOD》, vol. 116, no. 2, 1 March 2010 (2010-03-01), pages 270 - 279, XP002618133, DOI: doi:10.1182/blood-2009-11-254755 *
SIBU BALAN ET AL.: "Site-Specific PEGylation of Protein Disulfide Bonds Using a Three-Carbon Bridge", 《BIOCONJUGATE CHEM.》, vol. 18, no. 1, 29 November 2006 (2006-11-29), pages 61 - 76, XP002470617, DOI: doi:10.1021/bc0601471 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111788220A (zh) * 2018-01-12 2020-10-16 财团法人牧岩生命科学研究所 体内持续释放重组凝血因子ⅷ及其制备方法

Also Published As

Publication number Publication date
JP2013525414A (ja) 2013-06-20
CL2012003039A1 (es) 2014-01-24
JP5870088B2 (ja) 2016-02-24
AP2012006575A0 (en) 2012-12-31
US20130150302A1 (en) 2013-06-13
CA2797058A1 (en) 2011-11-03
IL222566A0 (en) 2012-12-31
KR20130055619A (ko) 2013-05-28
WO2011135307A1 (en) 2011-11-03
EP2563402A1 (en) 2013-03-06
CO6660443A2 (es) 2013-04-30
GB2492935B8 (en) 2014-10-29
CR20120579A (es) 2013-04-25
EA201290938A1 (ru) 2013-04-30
GB2492935A (en) 2013-01-16
IL222566A (en) 2017-12-31
ECSP12012314A (es) 2013-05-31
BR112012027590A2 (pt) 2016-08-09
PH12012502150A1 (en) 2013-02-04
GB2492935A8 (en) 2014-10-29
PE20130254A1 (es) 2013-03-16
ZA201208989B (en) 2014-02-26
HK1173946A1 (en) 2013-05-31
RU2012144555A (ru) 2014-06-10
GB2492935B (en) 2014-04-30
NZ603939A (en) 2013-08-30
GB201007357D0 (en) 2010-06-16
AU2011247147A1 (en) 2013-01-10
MX2012012683A (es) 2013-04-03
MY160922A (en) 2017-03-31
SG184906A1 (en) 2012-11-29
NI201200160A (es) 2013-04-19
AU2011247147B2 (en) 2014-09-18
GB201220667D0 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
AU2011247147B2 (en) Conjugated blood coagulation Factor VIII
CN102971013B (zh) 缀合的凝血因子VIIa
CN102112156B (zh) 凝血因子viii聚合物偶联物
AU2009239641B2 (en) Factor IX conjugates with extended half-lives
JP5022231B2 (ja) ポリマー−フォンビルブラント因子結合体
BRPI0720282B1 (pt) Construção proteica, composição farmacêutica, e, kit
JP2019520392A (ja) ヒト酵素媒介性シスチン枯渇
Shi et al. Site-specific PEGylation of human growth hormone by mutated sortase A
JP2015155469A (ja) 第ｆｖｉｉｉ因子ポリマー結合体
JP2018115170A (ja) 第ｆｖｉｉｉ因子ポリマー結合体
JP2019514859A (ja) 病的な筋肉減少および筋力低下の処置のためのｎｏｐｅ
HK1155939B (en) Factor viii polymer conjugates

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20171114

AD01 Patent right deemed abandoned